Pazopanib-induced organizing pneumonia in a patient with leiomyosarcoma: A case report

Chie Watanabe, Jun Miyata, Kotoba Esaki, Ryohei Suematsu, Tomoya Sano, Takayuki Yamamoto, Hisashi Sasaki, Yohei Maki, Yoichi Tagami, Yoshifumi Kimizuka, Yuji Fujikura, Keiichi Ito, Akihiko Kawana

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Pazopanib, a multityrosine kinase inhibitor used for treating malignant soft tissue tumors, rarely causes adverse events associated with the respiratory system. We report a case of a 73-year-old male with leiomyosarcoma treated with pazopanib. Four months after treatment initiation, chest computed tomography showed bilateral patchy consolidation and ground-glass opacities. Bronchoscopy revealed increased lymphocytes in the bronchoalveolar lavage fluid. Histological analysis of lung tissue demonstrated intraluminal fibrotic changes in alveolar spaces. According to these findings, we diagnosed the patient with pazopanib-induced organizing pneumonia. To best of our knowledge, this is the first report of such a case.

Original languageEnglish
Article number101112
JournalRespiratory Medicine Case Reports
Publication statusPublished - 2020
Externally publishedYes


  • Adverse event
  • Drug-induced lung injury
  • Leiomyosarcoma
  • Multityrosine kinase inhibitor
  • Organizing pneumoniae
  • Pazopanib

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Pazopanib-induced organizing pneumonia in a patient with leiomyosarcoma: A case report'. Together they form a unique fingerprint.

Cite this